Linezolid: a safer and effective substitute to aminoglycoside in the treatment of actinomycetoma by Nocardia species
International Journal of Dermatology · 2023
DOI: 10.1111/ijd.16764 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Dermatology, 2023. Verfasst von Namrata Chhabra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, All India Institute of Medical Sciences, Raipur, 492099, Chhattisgarh, India. Hauptthemen laut MEDLINE: Nocardia, Mycetoma, Nocardia Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Actinomycetoma is chronic, suppurative, granulomatous infection caused by bacteria and requires prolonged antibiotic therapy preferrably in combinations. Nephrotoxicity is a common side effect of aminoglycosides used in the management of actinomycetoma. We report here two cases of actinomycetoma due to Nocardia species who received linezolid as a substitute to aminoglycosides after developing nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, All India Institute of Medical Sciences, Raipur, 492099, Chhattisgarh, India.
ORCID-Profile: Namrata Chhabra
Zitieren
APA
Chhabra, N., Sri, P., & Ganguly, S. (2023). Linezolid: a safer and effective substitute to aminoglycoside in the treatment of actinomycetoma by Nocardia species. International Journal of Dermatology. https://doi.org/10.1111/ijd.16764
Vancouver
Chhabra N, Sri P, Ganguly S. Linezolid: a safer and effective substitute to aminoglycoside in the treatment of actinomycetoma by Nocardia species. International Journal of Dermatology. 2023. doi:10.1111/ijd.16764
BibTeX
@article{Chhabra2023,
author = {Chhabra, Namrata and Sri, Preethaa and Ganguly, Satyaki},
title = {Linezolid: a safer and effective substitute to aminoglycoside in the treatment of actinomycetoma by Nocardia species},
journal = {International Journal of Dermatology},
year = {2023},
doi = {10.1111/ijd.16764}
}
EUVIMED